Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imlifidase - Hansa Biopharma AB

Drug Profile

Imlifidase - Hansa Biopharma AB

Alternative Names: HMed-IdeS; IDEFIRIX; IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinase

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hansa Medical AB
  • Developer Hansa Biopharma AB; Linkoping University; University College London
  • Class Antibacterials; Antineoplastics; Antirheumatics; Bacterial proteins; Endopeptidases; Enzymes
  • Mechanism of Action Immunoglobulin modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-glomerular basement membrane disease; Guillain-Barre syndrome; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Transplant rejection
  • Phase II Anti-glomerular basement membrane disease; Guillain-Barre syndrome; Thrombotic thrombocytopenic purpura
  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 31 Oct 2019 Hansa Biopharma intends to launch imlifidase in 2020
  • 24 Sep 2019 Hansa Biopharma plans a follow-up meeting with the US FDA in November 2019
  • 18 Sep 2019 Pooled efficacy analysis from the phase II trials in Transplant rejection presented at the 19th Congress of the European Society for Organ Transplantation (ESOT-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top